In the fourth quarter of 2023, the Biden administration finalized updated procedures for conducting cost-benefit analysis and encouraging public participation in meetings about regulations. Advocates for scientific integrity commented on new draft scientific integrity policies. The Supreme Court responded to public concerns about its ethics by producing a Code of Conduct that lacks an enforcement mechanism, and it prepared to rule on cases that will determine whether agency experts or judges have more power over regulations and drug approvals.
Biden administration updates processes for reviewing regulations
On his first day in office, President Biden signed a memorandum that tasked the White House Office of Management and Budget (OMB) with improving and modernizing regulatory review. OMB—and specifically, the Office of Information and Regulatory Affairs (OIRA) within…
Read the full article originally published at blog.ucsusa.org.